Basecamp Research announced a $140 million Series C funding round on September 23. According to Reuters, the round valued it at approximately $800 million. S32 led the investment, with participation from NVIDIA, Anthropic's Anthology Fund, Catalio Capital Management, NATO Innovation Fund, Rockefeller Foundation and Singular.
The London-based company develops biological models based on datasets collected from a wide range of ecosystems. It wants to use these models to design proteins, genetic payloads and delivery systems for genetic medicines and cell therapies.
The round is large, but it is not proof that the medicines the company aims to develop have already demonstrated efficacy in humans.
What Basecamp is trying to build
AI companies in biology take a different approach from companies training language models on text. For Basecamp, the raw material is biological information: sequences, evolutionary relationships and patterns found in different organisms.
The company says its database lets models learn broad biological diversity and propose designs for new proteins and genetic mechanisms. The idea is to use knowledge found in nature to expand the space of possibilities searchable during drug development.
This is an interesting AI use, but there is a long distance between a model proposing a molecule or genetic component and an approved medicine. The path requires laboratory experiments, safety testing, preclinical studies, human trials and regulatory approval.
Who invested?
S32 led the round. Investors also include NVIDIA and Anthropic's Anthology Fund. It is important to distinguish investment by a fund connected to Anthropic's ecosystem from direct investment by Anthropic itself, unless it was reported that way.
NATO Innovation Fund and Rockefeller Foundation also participated, adding to a mix of investors from technology, biotech and institutions interested in scientific research.
Reuters reported a valuation of approximately $800 million, but it was not stated whether this was pre-money or post-money. The company also did not publish revenue, profitability or the commercial economics of licenses and partnerships.
Why investors are interested now
AI for biology has attracted large investments in recent years because models can search enormous spaces, rank candidates and help design experiments. The promise is to shorten certain research stages and find candidates difficult to reach through traditional methods alone.
But the distance between "AI drug discovery" and a successful medicine requires caution. A funding round is not a clinical result, a benchmark is not a human trial, and a model generating an interesting candidate still requires full scientific validation.
Basecamp says the new money will support programmable genetic medicines and advance therapeutic programs. The research dossier did not state which programs have already reached regulated human trials or provide clinical timelines.
What to watch
The next step is to see which programs move from computational research to practical experiments, whether the company publishes data showing an advantage over other methods, and whether commercial partnerships start generating revenue.
The round gives Basecamp significant resources to expand research. It also illustrates that the market continues betting on the connection between foundation models and biology. For now, however, the medical value of future medicines still needs to be proven experimentally, not just in a model.
Valuation and science are different things
The reported $800 million valuation reflects the funding round, not an independent assessment of scientific quality. Participation by NVIDIA, Anthology Fund and institutional bodies is also not proof that a particular drug candidate will reach the market.
Assessing scientific progress will require following publications, experiments and concrete collaborations. For a company in this field, the achievement more important than the funding round would be consistent progress from models and simulations to results reproducible in the laboratory and later, if they get there, in clinical studies too.